Dr Gholam on Camrelizumab Plus Rivoceranib in Unresectable H

Pierre Gholam, MD, discusses findings from the phase 3 CARES-310 trial of camrelizumab plus rivoceranib in patients with unresectable hepatocellular carcinoma.

Related Keywords

United States , Pierre Gholam , Digestive Health Research Institute , Department Of Medicine , Case Western Reserve University , School Of Medicine , D , Cares 310 Trial , Nct03764293 , Camrelizumab Plus Rivoceranib , Patients With Unresectable Hepatocellular Carcinoma ,